Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
380.5M
Cash
89.38M
Avg Qtr Burn
-17.39M
Short % of Float
13.15%
Insider Ownership
6.98%
Institutional Own.
63.64%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AZSTARYS (KP415) (serdexmethylphenidate and dexmethylphenidate) Details Attention deficit hyperactivity disorder | Approved Quarterly sales | |
Approved Quarterly sales | ||
MIPLYFFA™ (arimoclomol) Details Rare genetic disease, Rare diseases, Niemann Pick Disease Type C | Approved Quarterly sales | |
Celiprolol Details Vascular Ehlers-Danlos Syndrome | Phase 3 Data readout | |
KP1077 (serdexmethylphenidate, SDX) Details EDS in Idiopathic Hypersomnia
| Phase 2 Update | |
KP1077 (serdexmethylphenidate, SDX) Details Narcolepsy, Sleeping disorder | Phase 1 Data readout | |
KP879 (Methylphenidate) Details Stimulant Use Disorder | Phase 1 Update |